Ruhe, HG, Huyser, J, Swinkels, JA, Schene, AH. Switching antidepressants after a first selective
serotonin reuptake inhibitor in major depressive disorder: a systematic
review. J Clin Psychiatry
2006; 67: 1836–55.
Rush, AJ, Trivedi, MH, Wisniewski, SR, Nierenberg, AA, Stewart, JW, Warden, D, et al. Acute and longer-term outcomes in depressed
outpatients requiring one or several treatment steps: a STAR*D
report. Am J Psychiatry
2006; 163: 1905–17.
Anderson, IM. Selective serotonin reuptake inhibitors versus
tricyclic antidepressants: a meta-analysis of efficacy and
tolerability. J Affect Disord
Cipriani, A, Geddes, JR, Furukawa, TA, Barbui, C. Metareview on short-term effectiveness and safety of
antidepressants for depression: an evidence-based approach to inform
clinical practice. Can J Psychiatry
2007; 52: 553–62.
Geddes, JR, Freemantle, N, Mason, J, Eccles, MP, Boynton, J. SSRIs versus other antidepressants for depressive
disorder. Cochrane Database Syst Rev
Fava, M, Uebelacker, LA, Alpert, JE, Nierenberg, AA, Pava, JA, Rosenbaum, JF. Major depressive subtypes and treatment
response. Biol Psychiatry
1997; 42: 568–76.
Katz, MM, Koslow, SH, Frazer, A. Onset of antidepressant activity: reexamining the
structure of depression and multiple actions of drugs.
1996; 4: 257–67.
Bagby, RM, Ryder, AG, Schuller, DR, Marshall, MB. The Hamilton Depression Rating Scale: has the gold
standard become a lead weight?
Am J Psychiatry
2004; 161: 2163–77.
Santor, DA, Coyne, JC. Examining symptom expression as a function of
symptom severity: item performance on the Hamilton Rating Scale for
Depression. Psychol Assess
2001; 13: 127–39.
Uher, R, Farmer, A, Maier, W, Rietschel, M, Hauser, J, Marusic, A, et al. Measuring depression: comparison and
integration of three scales in the GENDEP study.
Lieberman, JA, Greenhouse, J, Hamer, RM, Krishnan, KR, Nemeroff, CB, Sheehan, DV, et al. Comparing the effects of antidepressants:
consensus guidelines for evaluating quantitative reviews of
2005; 30: 445–60.
Ragland, DR. Dichotomizing continuous outcome variables:
dependence of the magnitude of association and statistical power on the
1992; 3: 434–40.
Streiner, DL. Breaking up is hard to do: the heartbreak of
dichotomizing continuous data. Can J
2002; 47: 262–66.
Mallinckrodt, CH, Clark, WS, David, SR. Accounting for dropout bias using mixed-effects
models. J Biopharm Stat
Leon, AC, Mallinckrodt, CH, Chuang-Stein, C, Archibald, DG, Archer, GE, Chartier, K. Attrition in randomized controlled clinical trials:
methodological issues in psychopharmacology. Biol
2006; 59: 1001–5.
Lane, P. Handling drop-out in longitudinal clinical trials: a
comparison of the LOCF and MMRM approaches. Pharm
Gueorguieva, R, Krystal, JH. Move over ANOVA: progress in analyzing
repeated-measures data and its reflection in papers published in the
Archives of General Psychiatry. Arch Gen
2004; 61: 310–7.
March, JS, Silva, SG, Compton, S, Shapiro, M, Califf, R, Krishnan, R. The case for practical clinical trials in
psychiatry. Am J Psychiatry
2005; 162: 836–46.
Sanchez, C, Bergqvist, PB, Brennum, LT, Gupta, S, Hogg, S, Larsen, A, et al. Escitalopram, the S-(+)-enantiomer of
citalopram, is a selective serotonin reuptake inhibitor with potent
effects in animal models predictive of antidepressant and anxiolytic
activities. Psychopharmacology (Berl)
2003; 167: 353–62.
Sanchez, C, Hyttel, J. Comparison of the effects of antidepressants and
their metabolites on reuptake of biogenic amines and on receptor
binding. Cell Mol Neurobiol
1999; 19: 467–89.
Taylor, D, Duncan, D. Plasma levels of tricyclics and related
antidepressants: are they necessary or useful?
1995; 19: 548–50.
Montgomery, SA, Asberg, M. A new depression scale designed to be sensitive to
change. Br J Psychiatry
1979; 134: 382–9.
Hamilton, M. Development of a rating scale for primary depressive
illness. Br J Clin Psychol
1967; 6: 278–96.
Beck, AT, Ward, CH, Mendelson, M, Mock, J, Erbaugh, J. An inventory for measuring
depression. Arch Gen Psychiat
1961; 4: 561–71.
Thissen, D, Chen, WH, Bock, D. MULTILOG 7. Scientific Software
World Health Organization. The ICD–10
Classification of Mental and Behavioural Disorders: Clinical Descriptions
and Diagnostic Guidelines. WHO,
American Psychiatric Association. Diagnostic and
Statistical Manual of Mental Disorder, (4th
Wing, JK, Sartorius, N, Ustin, TB. Diagnosis and Clinical Management in Psychiatry. A
Reference Manual for SCAN. World Health
Little, T and Rubin, D. Analysis with Missing Data. John
Wiley & Sons, 1987.
StataCorp. Stata statistical software: release
10. Stata Corp LP,
Faries, D, Herrera, J, Rayamajhi, J, DeBrota, D, Demitrac, M, Potter, WZ. The responsiveness of the Hamilton Depression Rating
Scale. J Psychiatric Res
Danish University Antidepressant Group (DUAG).
Clomipramine dose-effect study in patients with
depression: clinical end points and pharmacokinetics.
Clin Pharmacol Ther
1999; 66: 152–65.
Serretti, A, Mandelli, L, Lorenzi, C, Pirovano, A, Olgiati, P, Colombo, C, et al. Serotonin transporter gene influences the
time course of improvement of ‘core’ depressive and somatic anxiety
symptoms during treatment with SSRIs for recurrent mood
disorders. Psychiatry Res
2007; 149: 185–93.
Bech, P, Gram, LF, Dein, E, Jacobsen, O, Vitger, J, Bolwig, TG. Quantitative rating of depressive
states. Acta Psychiatr Scand
1975; 51: 161–70.
Embretson, SE, Reise, SP. Item Response Theory for Psychologists.
Lawrence Erlbaum Associates,
Perlis, RH, Purcell, S, Fava, M, Fagerness, J, Rush, AJ, Trivedi, MH, et al. Association between treatment-emergent
suicidal ideation with citalopram and polymorphisms near cyclic adenosine
monophosphate response element binding protein in the STAR*D
study. Arch Gen Psychiatry
2007; 64: 689–97.
Davidson, J, Turnbull, CD. Diagnostic significance of vegetative symptoms in
depression. Br J Psychiatry
1986; 148: 442–6.
Moller, HJ. Methodological aspects in the assessment of severity
of depression by the Hamilton Depression Scale.
Eur Arch Psychiatry Clin Neurosci
2001; 251 (suppl 2):
Serretti, A, Cusin, C, Benedetti, F, Mandelli, L, Pirovano, A, Zanardi, R, et al. Insomnia improvement during antidepressant
treatment and CLOCK gene polymorphism. Am J Med
Genet B Neuropsychiatr Genet
2005; 137: 36–9.
Khan, A, Kolts, RL, Thase, ME, Krishnan, KR, Brown, W. Research design features and patient characteristics
associated with the outcome of antidepressant clinical
trials. Am J Psychiatry
2004; 161: 2045–9.
Walsh, BT, Seidman, SN, Sysko, R, Gould, M. Placebo response in studies of major depression:
variable, substantial, and growing. JAMA
2002; 287: 1840–7.
Leon, AC, Marzuk, PM, Portera, L. More reliable outcome measures can reduce sample
size requirements. Arch Gen Psychiatry
1995; 52: 867–71.
Brookes, ST, Whitely, E, Egger, M, Smith, GD, Mulheran, PA, Peters, TJ. Subgroup analyses in randomized trials: risks of
subgroup-specific analyses; power and sample size for the interaction
test. J Clin Epidemiol
2004; 57: 229–36.
Hotopf, M, Hardy, R, Lewis, G. Discontinuation rates of SSRIs and tricyclic
antidepressants: a meta-analysis and investigation of
heterogeneity. Br J Psychiatry
1997; 170: 120–7.
Joyce, PR, Mulder, RT, Luty, SE, Sullivan, PF, McKenzie, JM, Abbott, RM, et al. Patterns and predictors of remission,
response and recovery in major depression treated with fluoxetine or
nortriptyline. Aust N Z J Psychiatry
2002; 36: 384–91.